Pharmacoeconomic considerations for inflammatory bowel disease in the era of biological therapies-Reference-Cited by-同舟云学术

Pharmacoeconomic considerations for inflammatory bowel disease in the era of biological therapies

Published:2007-10 Issue:1 Volume:1 Page:101-112
ISSN:1747-4124
Container-title:Expert Review of Gastroenterology & Hepatology
language:en
Short-container-title:Expert Review of Gastroenterology & Hepatology

Author:

Thomas Tojo,Cohen Russell D

Publisher

Informa UK Limited

Subject

Gastroenterology,Hepatology

Link

http://www.tandfonline.com/doi/pdf/10.1586/17474124.1.1.101

Reference61 articles.

1. Inflammatory Bowel Disease

2. Hanauer SB, Cohen RD, Becker RV 3rd, Larson LR, Vreeland mg. Advances in the management of Crohn’s disease: economic and clinical potential of infliximab.Clin Ther,20(5), 1009–1028 (1998).

3. Inflammatory Bowel Disease

4. Annual cost of care for Crohn's disease: a payor perspective

5. The Cost of Hospitalization in Crohn's Disease

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Indirect health costs in ulcerative colitis and Crohn’s disease: a systematic review and meta-analysis;Expert Review of Pharmacoeconomics & Outcomes Research;2015-02-06

2. A Systematic Review of Economic Studies on Biological Agents Used to Treat Crohn’s Disease;Inflammatory Bowel Diseases;2013-11

3. Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States;Inflammatory Bowel Diseases;2011-07

4. The New Economic Reality in the World of IBD;Inflammatory Bowel Disease;2011

5. Si-Ni-San, a traditional Chinese prescription, and its active ingredient glycyrrhizin ameliorate experimental colitis through regulating cytokine balance;International Immunopharmacology;2009-11